ResMed Stock Slides -8.8% With A 5-Day Losing Spree
ResMed (RMD) – a developer of medical devices and cloud-based healthcare software – hit a 5-day losing streak, with cumulative losses over this period amounting to -8.8%. The company’s market cap has crashed by about $3.3 Bil over the last 5 days and currently stands at $34 Bil.
Is this opportunity or trap? There is not much to fear in RMD stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive (For details, see Buy or Sell RMD).
But here is the interesting part. You are reading about this -8.8% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- Steel Dynamics Earnings: Record Shipments And Margin Expansion Drive A Strong Quarter
- IQV Looks Smarter Buy Than Danaher Stock
- Robinhood Stock: The Multiple Tells The Wrong Story
- How ISRG Just Secured The U.S. Market
- How UNH Stock Is Trading Short-Term Margins For Long-Term Moats
- Key Metrics To Track For Capital One After Its Q1 Earnings Miss
The following table summarizes the return for RMD stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | RMD | S&P 500 |
|---|---|---|
| 1D | -0.1% | 1.0% |
| 5D (Current Streak) | -8.8% | -1.4% |
| 1M (21D) | -6.2% | -2.0% |
| 3M (63D) | -8.4% | -2.9% |
| YTD 2026 | -4.0% | -2.1% |
| 2025 | 6.3% | 16.4% |
| 2024 | 34.2% | 23.3% |
| 2023 | -16.5% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: RMD Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 42 S&P constituents with 3 days or more of consecutive gains and 36 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 32 | 17 |
| 4D | 10 | 5 |
| 5D | 0 | 4 |
| 6D | 0 | 6 |
| 7D or more | 0 | 4 |
| Total >=3 D | 42 | 36 |
Key Financials for ResMed (RMD)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $4.7 Bil | $5.1 Bil |
| Operating Income | $1.4 Bil | $1.7 Bil |
| Net Income | $1.0 Bil | $1.4 Bil |
Last 2 Fiscal Quarters:
| Metric | 2026 FQ1 | 2026 FQ2 |
|---|---|---|
| Revenues | $1.3 Bil | $1.4 Bil |
| Operating Income | $462.3 Mil | $497.6 Mil |
| Net Income | $348.5 Mil | $392.6 Mil |
The losing streak RMD stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.